Fighting Hard-to-Treat Cancers...Dan Schmitt, President & CEO, Actuate Therapeutics

In time for the 2026 ASCO Annual Meeting in Chicago, we're highlighting 3 BioTech companies shaping the future of cancer treatment:
On this episode of BioTech Nation, Dan Schmitt of Actuate Therapeutics talks about a new kind of drug showing positive early results in hard-to-treat cancer - including adult pancreatic cancer, and two pediatric cancers. So, what’s next? Global collaborations, international trials, and efforts into different types of cancer…and they’re showing no sign of slowing down.
Fighting Hard-to-Treat Cancers...Dan Schmitt, President & CEO, Actuate Therapeutics
Broadcast by